DOCSLIB.ORG

Recruitment of Leukemic Cells from G 0 Phase of the Cell Cycle By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recruitment of Leukemic Cells from G 0 Phase of the Cell Cycle By Leukemia (2003) 17, 2049–2059 & 2003 Nature Publishing Group All rights reserved 0887-6924/03 $25.00 www.nature.com/leu CORRESPONDENCE Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin Leukemia (2003) 17, 2049–2051. doi:10.1038/sj.leu.2403085 were not affected by daunorubicin-induced cell death. To analyze whether a similar cell cycle-specific sensitivity to Ara-C TO THE EDITOR and daunorubicin was observed in other leukemic cell lines, we analyzed four acute lymphoblastic leukemia cell lines and one Although the majority of patients with acute myeloid leukemia CML blast crisis cell line, which were generated in our (AML) responds to initial treatment, relapse of the disease occurs laboratory by culturing of leukemic blasts from five different in a significant percentage of these patients.1 The cell cycle patients in serum-free medium at high cell concentrations until status of leukemic cells may play an important role in the spontaneous sustained proliferation of the leukemic cells response to treatment of leukemic cells. Especially, the broadly occurred. These cell lines cytogenetically and phenotypically used cytotoxic agent Cytarabine (Ara-C) has been demonstrated resembled the primary leukemia. Figure 1b shows the median to exert its action via intercalation into the DNA of cells cell cycle distribution within these cell lines after incubation for À6 specifically in the S phase of the cell cycle, and sensitivity to this 48 h in medium alone, or in medium containing 1 Â 10 M Ara- agent is therefore described to be specific for cells in active cell C or daunorubicin. As expected, Ara-C-induced cell death 2 cycle. The role of the cell cycle in sensitivity of leukemic cells resulted in a deletion of cells from cycling S and G2/M phases, to anthracyclins like daunorubicin remains largely unknown. resulting in relative enrichment for cells in G0 and G1 phases. In We hypothesized that a fraction of noncycling leukemic contrast, daunorubicin-induced cell death resulted in a deletion (precursor) cells residing in dormancy might be unresponsive to of cells from both activated G1 phase and cycling S and G2/M chemotherapy. To test this hypothesis, we determined in a pilot phases, resulting in a major enrichment of cells in G0 phase. study the in vivo cell cycle specificity of chemotherapeutic These data illustrated the specificity of daunorubicin not only for treatment by analysis of the cell cycle distribution of leukemic cells in active cell cycle, but also for noncycling cells in the blasts freshly isolated from the peripheral blood of three patients activated G1 phase of the cell cycle. with AML at diagnosis and at multiple consecutive days after The AML-193 cell line model was used to further investigate in vivo treatment with Ara-C, daunorubicin, and etoposide. the influence of manipulation of the cell cycle status of leukemic Detailed cell cycle analysis was performed by combined ki-67 cells on chemotherapy sensitivity. As described previously, it is staining and propidium iodide (PI) DNA staining. Ki-67 is a possible to separately manipulate the cell cycle status and the nuclear protein which is absent in G0 phase and present in all proliferative capacity of these AML-193 cells using GM-CSF and other phases of the cell cycle,3 thereby facilitating the interferon (IFN) treatment.4 Three AML-193 subcell lines were discrimination between cells in resting G0 phase, activated G1 generated by culturing of cells either in the absence of cytokines phase, and cycling S or G2/M phase. Table 1 shows the total (control), in the presence of 1000 U/ml IFN-g, or in the presence nuclear cell counts, the percentages of leukemic blasts, and the of 500 U/ml IFN-a, as described previously.4 GM-CSF was used cell cycle distribution of the cells measured in time during to induce proliferation in these cells. None of these cell cycle chemotherapy administration. Already after 1 day of treatment, manipulations did induce apoptosis. The long-term culture a decrease in the number of cycling cells was noticed. In the period in the presence of IFN-g did not affect the proliferation following days, a further deletion of all activated ki-67 positive rate of the cells in the presence or absence of GM-CSF (data not cells was observed, resulting in a profound enrichment for cells shown). However, IFN-a treatment induced a 2.5-fold decrease in the resting G0 phase of the cell cycle. This relative enrichment in both baseline proliferation and proliferation in the presence of for cells in G0 phase could in part be explained by the GM-CSF. Detailed cell cycle analysis of cells cultured in the enrichment for normal T and B cells. However, even the presence or absence of GM-CSF and interferons was performed. leukemic population in G0 phase of the cell cycle appeared to As shown in Figure 2, in control AML-193 cells cultured in the be protected from the cytotoxic effects of the treatment. absence of GM-CSF as well as interferons, most cells were in To investigate in more detail the cell cycle specificity of resting G0 phase (66%), 19% of cells were in G1 phase, and daunorubicin, we used the human myeloid leukemic cell line 15% in S or G2/M phase (n ¼ 20). Long-term interferon treatment AML-193 as a model, and studied the cell cycle distribution of of control cells induced a significant increase in activated G1 viable cells within this cell line prior to and after 40 h of cells to 31% in IFN-g- and 27% in IFN-a-treated cells chemotherapy exposure. As shown in Figure 1a, AML-193 cells (Po0.0001). Small but significant higher percentages of cells cultured in medium contained cells in resting G0 phase (lower in S or G2/M phase were observed in IFN-g-treated cells (21%) left quadrant), cells in activated G1 phase (lower right quadrant), and IFN-a-treated cells (18%), as compared to control cells and cycling cells in S or G2/M phase (upper right quadrant). As (Po0.01). These increases coincided with a decrease in the À6 expected after 40 h of incubation, 10 M Ara-C-induced number of cells in resting G0 phase to 48% in IFN-g-treated complete deletion of the cycling S or G2/M compartment was cells, and to 55% in IFN-a-treated cells. Induction of prolifera- observed, whereas noncycling cells in resting G0 phase and tion with GM-CSF resulted in increased percentages of cells in activated G1 phase of the cell cycle were protected. In contrast, activated G1 phase (45%) and in the cycling S/G2/M phase À6 after 40 h of exposure to 10 M daunorubicin, both cells from (34%). In the presence of GM-CSF, IFN treatment did not exert the cycling S/G2/M compartment and the activated G1 an additive effect on the cell cycle distribution. These results compartment were deleted. Only cells in the resting G0 phase illustrate that long-term interferon treatment of AML-193 cells Correspondence 2050 Table 1 Cell cycle distribution after in vivo chemotherapy Pt Gender/age FAB class Time point WBC (106/ml) % blasts % lymphocytes Cell cycle distribution G0 G1 S/G2/M 1 m/29 M4 Day 0 64 30 6 30 85 9 Day 1 75 23 2 6.4 82 10 Day 2 80 18 2 1.7 58 31 Day 3 92 7 1 0.7 40 59 2 f/45 M5 Day 0 80 13 7 38.3 90 4 Day 1 54 44 2 7.9 82 12 Day 2 ND ND ND ND ND ND Day 3 94 4 2 0.5 57 21 3 m/35 M1 Day 0 52 45 3 86.2 95 1 Day 1 85 14 1 76.6 91 4 Day 2 ND ND ND ND ND ND Day 3 72 28 0 5.8 74 9 WBC ¼ white blood cell count; ND ¼ not done. The cell cycle distribution within the total nuclear cell population is listed at diagnosis and at 1, 2, and 3 days after chemotherapy administration. Owing to logistic problems, day 2 is missing in patients 2 and 3. Figure 2 Cell cycle distribution after interferon treatment in the absence and presence of GM-CSF. Cell cycle distribution was analyzed by combined ki-67/propidium iodide DNA staining. The # percentages of cells in G0 phase (’), G1 phase ( ), S phase ( ), and Figure 1 Cell cycle specificity of daunorubicin and Ara-C. (a) Cell G /M phase (&) were determined. cycle analysis of viable AML-193 cells by PI/ki-67 analysis after 40 h of 2 À6 incubation in medium alone, or in medium containing 10 M -6 daunorubicin, or 10 M Ara-C. (b) Cell cycle analysis of viable cells of five ALL/CML cell lines after 40 h of incubation in medium alone, or À6 À6 ¼ g a in medium containing 10 M Ara-C or 10 M daunorubicin. The after 40 h (n 30). Activation of control cells by IFN- or IFN- percentages of cells in G0 phase (’), G1 phase ( ), S phase (&), and without induction of proliferation induced a two-fold increase in " G2/M phase ( ) were determined. The mean percentages of cells in median sensitivity to daunorubicin after 24 h, resulting in 48% every cell cycle fraction7s.d. are listed. lysis (n ¼ 20; Po0.0001) and 36% lysis (n ¼ 15; P ¼ 0.02) in IFN-g- and IFN-a-treated cells, respectively. The same increase in sensitivity to daunorubicin was found after induction of proliferation with GM-CSF (n ¼ 40; Po0.0001).
Load more

Recommended publications
  • Epithelial Cell Death Analysis of Cell Cycle by Flow Cytometry White Paper
    Epithelial Cell Death Analysis of Cell Cycle by Flow Cytometry White Paper Authors: Savithri Balasubramanian, John Tigges, Vasilis Toxavidis, Heidi Mariani. Affiliation: Beth Israel Deaconess Medical Center Harvard Stem Cell Institute a Beckman Coulter Life Sciences: Epithelial Cell Death Analysis of Cell Cycle by Flow Cytometry PRINCIPAL OF TECHNIQUE Background: Cell cycle, or cell-division cycle, is the series of events that takes place in a cell leading to its division and duplication (replication). In cells without a nucleus (prokaryotic), cell cycle occurs via a process termed binary fission. In cells with a nucleus (eukaryotes), cell cycle can be divided in two brief periods: interphase—during which the cell grows, accumulating nutrients needed for mitosis and duplicating its DNA—and the mitosis (M) phase, during which the cell splits itself into two distinct cells, often called «daughter cells». Cell-division cycle is a vital process by which a single-celled fertilized egg develops into a mature organism, as well as the process by which hair, skin, blood cells, and some internal organs are renewed. Cell cycle consists of four distinct phases: G1 phase, S phase (synthesis), G2 phase (collectively known as interphase) and M phase (mitosis). M phase is itself composed of two tightly coupled processes: mitosis, in which the cell’s chromosomes are divided between the two daughter cells, and cytokinesis, in which the cell’s cytoplasm divides in half forming distinct cells. Activation of each phase is dependent on the proper progression and completion of the previous one. Cells that have temporarily or reversibly stopped dividing are said to have entered a state of quiescence called G0 phase.
    [Show full text]
  • P53 Phosphorylation and Association with Murine Double Minute 2, C-Jun
    [CANCER RESEARCH 60, 896–900, February 15, 2000] Advances in Brief p53 Phosphorylation and Association with Murine Double Minute 2, c-Jun ARF NH2-Terminal Kinase, p14 , and p300/CBP during the Cell Cycle and after Exposure to Ultraviolet Irradiation1 Thomas Buschmann, Victor Adler, Ekaterina Matusevich, Serge Y. Fuchs, and Ze’ev Ronai2 Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029 Abstract though the mechanisms underlying the ability of p53 to elicit such opposing effects are yet to be identified, independent studies point to p53 phosphorylation and association with proteins is implicated in its a different set of p53 regulators and effectors that are affected by p53 stability and activity. We have compared the association of DNA-bound in each of these scenarios. and overall pools of p53 with murine double minute 2 (Mdm2), c-Jun NH -terminal kinase (JNK), p300/CBP, and p14ARF during cell cycle In studying the regulation of p53 stability, we demonstrated previ- 2 ously that, in Swiss 3T3 cells, JNK and Mdm2 target p53 degradation progression. Whereas DNA-bound p53 associates with JNK at G0-G1 and in different phases of the cell cycle (7). In this study, we have with Mdm2 and p300 during S and G2-M phases, the general pool of p53 was found in complex with JNK and Mdm2 almost throughout the cell compared the association of subpopulations of p53 with proteins cycle. Phosphorylation of p53 at serines 9, 15, and 20 is at the highest levels implicated in stability and activity of p53 and monitored the pattern of at G1 and at serines 37 and 392 during G2-M phase.
    [Show full text]
  • A P53-Responsive Mirna Network Promotes Cancer Cell Quiescence Ting La1, Guang Zhi Liu2, Margaret Farrelly1, Nicole Cole3, Yu Chen Feng1, Yuan Yuan Zhang1, Simonne K
    Published OnlineFirst October 9, 2018; DOI: 10.1158/0008-5472.CAN-18-1886 Cancer Tumor Biology and Immunology Research A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence Ting La1, Guang Zhi Liu2, Margaret Farrelly1, Nicole Cole3, Yu Chen Feng1, Yuan Yuan Zhang1, Simonne K. Sherwin1, Hamed Yari1, Hessam Tabatabaee1, Xu Guang Yan1, Su Tang Guo4, Tao Liu5, Rick F. Thorne2,6, Lei Jin7, and Xu Dong Zhang1,2 Abstract Cancer cells in quiescence (G0 phase) are resistant to miRNA-455-3p targeted CDK2-associated cullin domain 1 death, and re-entry of quiescent cancer cells into the cell- (CAC1), which enhanced CDK2-mediated phosphorylation cycle plays an important role in cancer recurrence. Here we of p27 necessary for its polyubiquitination. Of note, the show that two p53-responsive miRNAs utilize distinct but gene encoding miRNA-27b-3p was embedded in the intron complementary mechanisms to promote cancer cell quies- of the chromosome 9 open reading frame 3 gene that was cence by facilitating stabilization of p27. Purified quiescent transcriptionally activated by p53. Similarly, the host gene B16 mouse melanoma cells expressed higher levels of of miRNA-455-3p, collagen alpha-1 (XXVII) chain, was also a miRNA-27b-3p and miRNA-455-3p relative to their prolif- p53 transcriptional target. Collectively, our results identify erating counterparts. Induction of quiescence resulted in miRNA-27b-3p and miRNA-455-3p as important regulators increased levels of these miRNAs in diverse types of human of cancer cell quiescence in response to p53 and suggest that cancer cell lines. Inhibition of miRNA-27b-3p or miRNA- manipulating miRNA-27b-3p and miRNA-455-3p may con- 455-3p reduced, whereas its overexpression increased, the stitute novel therapeutic avenues for improving outcomes of proportion of quiescent cells in the population, indicating cancer treatment.
    [Show full text]
  • The Cyclin-Dependent Kinase Inhibitor and Tumor Suppressor Locus P16/INK4A- P14arf and Regulation of the Transition Into and out of the Cell Cycle
    The Cyclin-Dependent Kinase Inhibitor and Tumor Suppressor Locus p16/INK4A- p14ARF and Regulation of the Transition Into and Out of the Cell Cycle by Payal Agarwal A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Auburn, Alabama May 7, 2012 Copyright, 2011 by Payal Agarwal Approved by Richard C. Bird, Chair, Professor of Pathobiology Bruce F. Smith, Professor of Pathobiology Frederik W. van Ginkel, Associate Professor of Pathobiology Anthony G. Moss, Associate Professor of Biological Sciences Abstract p16/INK4A/CDKN2A is an important tumor suppressor gene located in the INK4A/ARF locus, which encodes a 16 kDa protein known as p16, and a 14 kDa protein known as p14ARF in humans. p16 arrests cell cycle in early G1 phase thereby inhibiting the binding of cyclin dependent kinase 4/6 with cyclinD1. This leaves the retinoblastoma protein (pRb) tumor suppressor hypo-phosphorylated and S phase transcription factor E2F bound and inactive. p14ARF expression up-regulates cyclin dependent kinase inhibitor p21, which inhibits the G1/S phase transition by stabilizing p53 expression upon disassociation from mdm2. We hypothesized that p16 has a role in exit from the cell cycle, becomes defective in cancer cells and has binding partners other than CDK4/CDK6 in quiescent or differentiated cells when their canonical target proteins are thought to be nonfunctional. We have hypothesized that INK4A/ARF encoded proteins perform important regulatory roles that are defective in canine mammary cancer and may cause loss of differentiation potential. Well characterized p16-defective canine mammary cancer cell lines, normal canine fibroblasts, and CMT-derived p16-transfected CMT cell clones, are used to investigate expression of p16 after serum starvation into quiescence followed by re-feeding to induce cell cycle re-entry.
    [Show full text]
  • Exit from Quiescence Displays a Memory of Cell Growth and Division
    ARTICLE DOI: 10.1038/s41467-017-00367-0 OPEN Exit from quiescence displays a memory of cell growth and division Xia Wang1,2, Kotaro Fujimaki1, Geoffrey C. Mitchell1,3, Jungeun Sarah Kwon1, Kimiko Della Croce1, Chris Langsdorf4, Hao Helen Zhang5 & Guang Yao1,6 Reactivating quiescent cells to proliferate is critical to tissue repair and homoeostasis. Quiescence exit is highly noisy even for genetically identical cells under the same environmental conditions. Deregulation of quiescence exit is associated with many diseases, but cellular mechanisms underlying the noisy process of exiting quiescence are poorly understood. Here we show that the heterogeneity of quiescence exit reflects a memory of preceding cell growth at quiescence induction and immediate division history before quiescence entry, and that such a memory is reflected in cell size at a coarse scale. The deterministic memory effects of preceding cell cycle, coupled with the stochastic dynamics of an Rb-E2F bistable switch, jointly and quantitatively explain quiescence-exit heterogeneity. As such, quiescence can be defined as a distinct state outside of the cell cycle while displaying a sequential cell order reflecting preceding cell growth and division variations. 1 Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA. 2 School of Biological and Medical Engineering, Hefei University of Technology, Hefei, Anhui 230009, China. 3 Department of Biology, Wofford College, Spartanburg, SC 29303, USA. 4 Molecular Probes, Thermo Fisher Scientific, Eugene, OR 97402, USA. 5 Department of Mathematics, University of Arizona, Tucson, AZ 85721, USA. 6 Arizona Cancer Centre, University of Arizona, Tucson, AZ 85719, USA. Xia Wang, Kotaro Fujimaki and Geoffrey C.
    [Show full text]
  • Detailed Description of Gene Signatures
    Detailed description of gene signatures Immune response gene signatures Four QTC clusters showed a significant association with immune response, QTC1, QTC8, QTC10, and QTC17. QTC1 was highly enriched for GO:0002376 immune system process (p=9.2x10-31) and GO:0046649 lymphocyte activation (7.1x10-7), QTC8 for GO:0002376 immune system processes (p=9.7x10-5), QTC10 for GO:0002474 antigen processing and presentation of peptide antigen via MHC class I (p=2.1x10-5), and QTC17 for the KEGG pathway hsa04060 cytokine-cytokine receptor interaction (p=2.3x10-5), suggesting that these gene clusters represents different aspects of the immune response system. QTC1 and QTC8 were highly correlated (r=0.85) whereas QTC10 and QTC17 appeared more independent. QTC1 and QTC8 were more strongly expressed in the MS2b.1 subtype whereas QTC10 and QTC17 were more strongly expressed in the MS2b2.2 subtype QTC1 and QTC8 were merged and subsets of immune-related genes are shown in Figures 1A and 1B. The signature had a prominent activated T-cell theme including key genes ranging from T-cell stimulatory chemokines, T-cell receptor complex genes, T-cell specific markers, as well as signal transducers and effector genes of cytotoxic T-cells. Among the early T-cell activator genes were CCL2, CCL5, IL2RA, IL2RB, and IL7R. CCL2 and CCL5 are known to be produced by tumor cells and induce transendothelial migration and chemotaxis of effector T-cells (Brown et al. 2007, Soria and Ben-Baruch, 2008). CCL5 co-localizes with tumor infiltrating leukocytes and the CCL5 concentrations correlates to CD8+ T-cell infiltration in the epithelial areas of tumors (Negus et al.
    [Show full text]
  • Cell Cycle ­ Wikipedia Cell Cycle from Wikipedia, the Free Encyclopedia
    11/8/2016 Cell cycle ­ Wikipedia Cell cycle From Wikipedia, the free encyclopedia The cell cycle or cell­division cycle is the series of events that take place in a cell leading to its division and duplication of its DNA (DNA replication) to produce two daughter cells. In bacteria, which lack a cell nucleus, the cell cycle is divided into the B, C, and D periods. The B period extends from the end of cell division to the beginning of DNA replication. DNA replication occurs during the C period. The D period refers to the stage between the end of DNA replication and the splitting of the bacterial cell into two daughter cells.[2] In cells with a nucleus, as in eukaryotes, the cell cycle is also divided into three periods: interphase, the mitotic (M) phase, and cytokinesis. During interphase, the cell grows, accumulating nutrients needed for mitosis, preparing it for cell division and duplicating its DNA. During the mitotic phase, the chromosomes separate. During the final stage, cytokinesis, the chromosomes and cytoplasm separate into two new daughter cells. To ensure the proper division of the cell, there are control mechanisms known as cell cycle checkpoints. Life Cycle of the cell The cell­division cycle is a vital process by which a single­celled fertilized egg develops into a mature organism, as well as the process by which hair, skin, blood cells, and some internal organs are renewed. After cell division, each of the daughter cells begin the interphase of a new cycle. Although the various stages of interphase are not usually morphologically distinguishable, each phase of the cell cycle has a distinct set of specialized biochemical processes that prepare the cell for initiation of cell division.
    [Show full text]
  • ABT-263 Induces G1/G0-Phase Arrest, Apoptosis and Autophagy in Human Esophageal Cancer Cells in Vitro
    Acta Pharmacologica Sinica 2017: 1632–1641 © 2017 CPS and SIMM All rights reserved 1671-4083/17 www.nature.com/aps Original Article ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro Qing-huan LIN, Fu-chang QUE, Chun-ping GU, De-sheng ZHONG, Dan ZHOU, Yi KONG, Le YU*, Shu-wen LIU* State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China Abstract Both the anti- and pro-apoptotic members of the Bcl-2 family are regulated by a conserved Bcl-2 homology (BH3) domain. ABT- 263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. But the anticancer mechanisms of ABT-263 have not been fully elucidated. In this study we investigated the effects of ABT-263 on human esophageal cancer cells in vitro and to explore its anticancer mechanisms. Treatment with ABT-263 dose-dependently suppressed the viability of 3 human esophageal cancer cells with IC50 values of 10.7±1.4, 7.1±1.5 and 8.2±1.6 μmol/L, in EC109, HKESC-2 and CaES-17 cells, respectively. ABT-263 (5–20 μmol/L) dose-dependently induced G1/G0-phase arrest in the 3 cancer cell lines and induced apoptosis evidenced by increased the Annexin V-positive cell population and elevated levels of cleaved caspase 3, cleaved caspase 9 and PARP.
    [Show full text]
  • The Cell Cycle
    www.arigobio.com The Cell Cycle Antibody˙Duo˙ELISA kit Cell Division G0 The G0 phase is a period in the cell cycle in which G2/M Checkpoint M cells exist in quiescent state. Depends on cell types, G0 phase can last 6 C / for few days to few years. y Oncogenes : 4 c K l i n Cyclins, Cyclin-Dependent D B C + + Kinases (CDKs), E2F, MYC, C D d MDM2. n i c l 2 c y Tumor Suppressors : G2 The C RB, p53, p21, p27, p57, p14ARF, G1 p16INK4a, p17, p18, p19, TGF-β Cell Cycle receptor, BRCA1, BRCA2, ATM. C y 2 c K lin D A C + + DNA Duplication CD inE K1/2 Cycl S G1/S Checkpoint Cell Content Doubled G1/S Checkpoint G2/M Checkpoint GF Contact DNA DNA Damage Withdrawal TGF-β Innibition Damage DNA repair GSK3β Smad3/4 ATM/ATR DNA-PK ATM/ATR BRCA1 p53 Ubiquitination INK4 p53 CHK2 CHK1/2 p16 p15 p27 p21 Ubiquitination MDM2 INK4 family Cip/Kip family 14-3-3 SKP2 Cdc25B/C MDM2 Nuclear Cdc25A p19ARF Export CDK4/6 CDK2 Nuclear p53 p300/PCAF cyclinD cyclinE Sequestration 14-3-3 p21Cip1 GADD45 Rb HDAC Nuclear Rb E2F DP-I E2F DP-I Export CDC2 cyclinB M phase Promoter OFF Promoter ON Progression Common Methods for Mammalian Cell Cycle Synchronization Cell Cycle Stage Blocked Method Proposed mechanism of action G0/G1 Serum Starvation Growth restriction Lovastin Inhibition of HMG-CoA reductase G1 Mimosine Inhibit Thymidine, nucleotide biosynthesis Thymidine Feedback inhibition of DNA replication G1/S Aphidicolin Inhibition of DNA polymerases Hydroxyurea Inhibition of ribonucleotide reductase Colchicine/Colcemide Inhibition of microtubule polymerization G2/M Nocodazole Inhibition of microtubule polymerization ARG30139 Cell Cycle Marker Antibody Panel (Cyclin B1, Cyclin E) The cell cycle is controlled by numerous mechanisms ensuring correct cell division.
    [Show full text]
  • The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
    International Journal of Molecular Sciences Review The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer 1,2, 1,2, 1,2, 1,2 1,2 Lei Ding y, Jiaqi Cao y, Wen Lin y, Hongjian Chen , Xianhui Xiong , Hongshun Ao 1,2, Min Yu 1,2, Jie Lin 1,2 and Qinghua Cui 1,2,* 1 Lab of Biochemistry & Molecular Biology, School of Life Sciences, Yunnan University, Kunming 650091, China; [email protected] (L.D.); [email protected] (J.C.); [email protected] (W.L.); [email protected] (H.C.); [email protected] (X.X.); [email protected] (H.A.); [email protected] (M.Y.); [email protected] (J.L.) 2 Key Lab of Molecular Cancer Biology, Yunnan Education Department, Kunming 650091, China * Correspondence: [email protected] The authors contributed equally to this work. y Received: 31 December 2019; Accepted: 24 February 2020; Published: 13 March 2020 Abstract: Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose catalytic activities are regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs are key regulatory enzymes involved in cell proliferation through regulating cell-cycle checkpoints and transcriptional events in response to extracellular and intracellular signals. Not surprisingly, the dysregulation of CDKs is a hallmark of cancers, and inhibition of specific members is considered an attractive target in cancer therapy. In breast cancer (BC), dual CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, combined with other agents, were approved by the Food and Drug Administration (FDA) recently for the treatment of hormone receptor positive (HR+) advanced or metastatic breast cancer (A/MBC), as well as other sub-types of breast cancer.
    [Show full text]
  • Infectious Delivery of the 132 Kb CDKN2A/CDKN2B Genomic DNA Region Results in Correctly Spliced Gene Expression and Growth Suppression in Glioma Cells
    Gene Therapy (2004) 11, 1195–1204 & 2004 Nature Publishing Group All rights reserved 0969-7128/04 $30.00 www.nature.com/gt RESEARCH ARTICLE Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells R Inoue, KA Moghaddam, M Ranasinghe, Y Saeki, EA Chiocca and R Wade-Martins1 Molecular Neuro-Oncology Laboratories, Neurosurgery Service, Massachusetts General Hospital-East and Harvard Medical School, Charlestown, MA, USA The expression of genes from genomic loci can be relatively these proteins are expressed from overlapping genes, complex, utilizing exonic, intronic and flanking sequences utilizing alternative splicing and promoter usage. The to regulate tissue and developmental specificity. Infectious delivered locus expresses each gene at physiological levels bacterial artificial chromosomes (iBACs) have been shown to and cellular responses (apoptosis versus growth arrest) deliver and express large genomic loci (up to 135 kb) into occur dependent on cellular p53 status, as expected. The primary cells for functional analyses. The delivery of large work further demonstrates the potential of the iBAC system genomic DNA inserts allows the expression of complex loci for the delivery of genomic loci whose expression is mediated and of multiple splice variants. Herein, we demonstrate for by complex splicing and promoter usage both for gene the first time that an iBAC will deliver and correctly express in therapy applications and functional genomics studies. human glioma cells the entire CDKN2A/CDKN2B genomic Gene Therapy (2004) 11, 1195–1204. doi:10.1038/ region, which encodes for at least three important cell-cycle sj.gt.3302284; Published online 27 May 2004 regulatory proteins (p16INK4a, p14ARF and p15INK4b).
    [Show full text]
  • Spindle Checkpoint Function Is Required for Mitotic Catastrophe Induced by DNA-Damaging Agents
    Oncogene (2004) 23, 6548–6558 & 2004 Nature Publishing Group All rights reserved 0950-9232/04 $30.00 www.nature.com/onc Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents Masayuki Nitta1,2,3, Osamu Kobayashi1,2,3, Shinobu Honda1, Toru Hirota1, Shinji Kuninaka1, Tomotoshi Marumoto1, Yukitaka Ushio2 and Hideyuki Saya*,1 1Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, University of Kumamoto, 1-1-1 Honjo, Kumamoto 860-8556, Japan; 2Department of Neurosurgery, Graduate School of Medical Sciences, University of Kumamoto, Kumamoto, Japan Mitotic catastrophe is an important mechanism for the ments such as chemotherapy and radiation. Most cancer induction of cell death in cancer cells by antineoplastic cells are deficient in G1 checkpoint function and agents that damage DNA. This process is facilitated by therefore fail to arrest in G1 phase on exposure to geno- defects in the G1 and G2 checkpoints of the cell cycle that toxic agents. Instead, they accumulate temporarily in are apparent in most cancer cells and which allow the cells G2 phase. However, given that the G2 checkpoint is to enter mitosis with DNA damage. We have now also partially impaired in cancer cells, they are unable characterized the dynamics of mitotic catastrophe induced to maintain G2 arrest and eventually die as they enter by DNA-damaging agents in p53-deficient cancer cells. mitosis (Fingert et al., 1986; Chan et al., 1999). This Cells that entered mitosis with DNA damage transiently process is known as mitotic catastrophe or mitotic death arrested at metaphase for more than 10 h without (Chan et al., 1999; Roninson et al., 2001).
    [Show full text]